FUJIFILM Biosciences and Virica Biotech strike deal to break the AAV manufacturing bottleneck
A new collaboration between FUJIFILM Biosciences and Ottawa-based Virica Biotech aims to address one of the most persistent constraints in gene therapy manufacturing: the cost-effective, large-scale production of adeno-associated virus (AAV) vectors. The partnership, announced on 8 April 2026, is supported by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) under the Canada–Japan Corporate Co-Innovation Program.
The manufacturing challenge behind gene therapy’s scaling problem
AAV vectors remain the dominant vehicle for in vivo gene delivery, yet their manufacture is notoriously resource-intensive. As clinical pipelines broaden to encompass more indications and larger patient populations, demand for high-quality AAV is outpacing what current production economics can sustainably support. Yield inefficiencies and process variability continue to drive up cost-of-goods, placing commercially viable gene therapies beyond the reach of many healthcare systems.
What the collaboration involves
The project will focus on integrating Virica’s proprietary Viral Sensitizer (VSE™) enhancer technology with FUJIFILM Biosciences’ BalanCD® HEK293 suspension cell culture media. Virica will optimise VSE formulations using its High-Throughput Virology (HTV™) platform alongside Design-of-Experiments (DoE) frameworks and analytical testing. FUJIFILM Biosciences will contribute expertise in media and feed supplement development, together with scale-up capabilities.
The intended output is an off-the-shelf enhancer–media combination that AAV producers – both academic and commercial – can adopt with minimal process changes, reducing barriers to implementation.
Dr Jean-Simon Diallo, Scientific Co-founder and Chief Executive Officer of Virica Biotech, said: “We see a strong fit between our VSE technology and FUJIFILM Biosciences BalanCD media portfolio. Following the recent launch of our CellVantage-AAV off-the-shelf enhancer, our goal is to provide an optimised formulation to deliver further AAV productivity gains specifically in the FUJIFILM Biosciences BalanCD HEK293 system.”
Yutaka Yamaguchi, Chairman and Chief Executive Officer at FUJIFILM Biosciences, commented: “We remain committed to offering integrated solutions that combine high-performance media with enabling technologies. Optimising Virica’s VSE-based enhancers with our FUJIFILM Biosciences BalanCD HEK293 system will help us deliver an easy-to-implement option for improving AAV yields and supporting efficient scale-up for our customers.”
For clinical laboratory scientists and process development teams working in viral vector manufacturing, this collaboration signals a move towards commercially available, system-optimised enhancer solutions that could reduce the complexity and cost of AAV production without requiring bespoke process redesign.
Yutaka Yamaguchi, Chairman and Chief Executive Officer at FUJIFILM Biosciences
Dr Jean-Simon Diallo, Scientific Co-founder and Chief Executive Officer of Virica Biotech
